Pregled bibliografske jedinice broj: 599047
Comparison of the "Ssdwlab 5.0.9" and "Fetal Medicine Foundation" Down syndrom screening softwares
Comparison of the "Ssdwlab 5.0.9" and "Fetal Medicine Foundation" Down syndrom screening softwares // Biochemia Medica 2012 ; 22(3):267-402 ; A17-A204 / Šimundić, AM (ur.).
Zagreb: Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012. str. A181-A182 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 599047 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Comparison of the "Ssdwlab 5.0.9" and "Fetal
Medicine Foundation" Down syndrom screening
softwares
Autori
Radeljak, A ; Podobnik Brlečić, P ; Ožvald, I ; Gebauer Vuković, B ; Podobnik, M ; Stojanović, N.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Biochemia Medica 2012 ; 22(3):267-402 ; A17-A204
/ Šimundić, AM - Zagreb : Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012, A181-A182
Skup
2nd European Joint Congress of European Federatioin of Clinical Chemistry and laboratory Medicine (EFCC) and European Union of Medical Specialists (UEMS)/ 7th Congrerss of Croatian Society of Medical Biochemistry and Laboratory Medicine (CSMBLM)
Mjesto i datum
Dubrovnik, Hrvatska, 10.10.2012. - 13.10.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Down syndrom ; screening softwares
Sažetak
Background. First trimetser screening by a combination of maternal age, fetal nuchal translucency and maternal serum free-b-hCG and PAPP-A can identify about 85-90% of fetuses with trisomy 21 and other mayor aneuploidies. The aim of this study was to compare risk calculations performed using two different softwares. materials and methods. PAPP-A and free-b-hCG concentrations were measured by electrochemiluminescent immunoassay /ECL) on Roche Elecsys analyzer. The obtained results were within the target values of internal and external quality assurance programme (UKNEQAS scheme for First Trimester Downs Syndrome Screening). Nuchal translucency was measured by sonographers with FMF Certificate of Competence. Risk calculations were performed using "SsdwLab 5.0.9" (Roche, certified by FMF) and "Fetal Medicine Foundation" softwares. Results. Patients (N=247) were devided into high, intermediate and low risk groups. The obtained distributions per group were: high risk 18 (7, 29%), intermediate risk 36 (14, 57%) and low risk 193(78, 14%)patients using SsdwLab 5.0.9 software vs. high risk 12 (4, 86%), intermediate risk 26 (10, 53%) and low risk 209 (84, 61%) patients using FMF software. 18 patients were classified as high risk by SsdwLab 5.0.9 vs. 10 (55, 6%) as high risk and 8 (44, 4%)as intermediate risk using FMF software. Only one fetus from the high risk group (by both softwares) was trisomy 21 positive, which was confirmed by amniocentesis. Conclusions. Comparing risk calculations performed using "SsdwLab 5.0.9" and "Fetal Medicine Foundation" softwares, we concluded that SSdwLab 5.0.9 calculates higher risk for the same input parameters. Further research will be aimed at discovering the causes of observed differences.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE